Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

J Clin Invest. 1988 Apr;81(4):1284-91. doi: 10.1172/JCI113446.

Abstract

Localized thrombosis was produced in the left anterior descending (LAD) coronary artery of open chest dogs by constricting a segment so as to produce greater than 90% stenosis (reducing blood flow to 40 +/- 10% of baseline), and placing a thrombus in the segment immediately proximal to the stenosis by inducing endothelial cell injury and instilling a mixture of blood and thrombin. Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) at a rate of 15-30 micrograms/kg per min for 30 or 60 min in eight dogs induced coronary artery reperfusion within 23 +/- 7 min (mean +/- SD), but reocclusion occurred despite heparin anticoagulation in all but one of these dogs within 7 +/- 5 min. Intravenous injection of 0.8 mg/kg of the F(ab')2 fragment of a monoclonal antibody (7E3) directed against the platelet GPIIb/IIIa receptor, prevented reocclusion in 10/10 dogs during an observation period of 2 h (P less than 0.001 vs. rt-PA alone). The antibody abolished ADP-induced platelet aggregation and markedly prolonged the bleeding time. Intravenous aspirin or dipyridamole prevented reocclusion for 1 h or more in only 2/7 and 1/6 dogs, respectively. We conclude that the monoclonal antibody is very effective in preventing reocclusion after successful thrombolysis of occluded coronary arteries with rt-PA.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Aspirin / therapeutic use
  • Coronary Disease / therapy*
  • Coronary Thrombosis / pathology
  • Coronary Thrombosis / therapy*
  • Dipyridamole / therapeutic use
  • Dogs
  • Immunoglobulin Fab Fragments / therapeutic use
  • Microscopy, Electron, Scanning
  • Platelet Aggregation
  • Platelet Membrane Glycoproteins / physiology*
  • Receptors, Cell Surface / physiology*
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Membrane Glycoproteins
  • Receptors, Cell Surface
  • Dipyridamole
  • Tissue Plasminogen Activator
  • Aspirin